Pablo E. Pergola
Expertise in
11
conditions

Dr. Pablo E. Pergola

Nephrology
Kidney Disease Clinic Of Central San Antonio
305 N Frio St, 
San Antonio, TX 
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
Kidney Disease Clinic Of Central San Antonio
305 N Frio St, 
San Antonio, TX 

Overview

Pablo Pergola is a Nephrologist practicing medicine in San Antonio, Texas.

Dr. Pergola is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Alport Syndrome, High Potassium Level, Chronic Kidney Disease, and Diabetic Nephropathy.

He is actively involved in clinical research, co-authoring 93 peer reviewed articles and participating in 12 clinical trials. Dr. Pergola is currently accepting new patients.

Specialties

Nephrology

Licenses

Internal Medicine in TX

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Kidney Disease Clinic of Central San Antonio
305 N Frio St, San Antonio, TX 78207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: Bardoxolone
Study Phase: Phase 3
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: Bardoxolone
Study Phase: Phase 3
A Phase 2 Trial to Evaluate Safety, Tolerability, and Efficacy of Bardoxolone Methyl in Patients With Chronic Kidney Disease at Risk of Rapid Progression
A Phase 2 Trial to Evaluate Safety, Tolerability, and Efficacy of Bardoxolone Methyl in Patients With Chronic Kidney Disease at Risk of Rapid Progression
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of CLBS201 Autologous Peripheral Blood-Derived CD34+ Cells in Subjects with Chronic Kidney Disease and Type 2 Diabetes Mellitus
A Phase 1 Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of CLBS201 Autologous Peripheral Blood-Derived CD34+ Cells in Subjects with Chronic Kidney Disease and Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: CLBS201
Study Phase: Phase 1
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis
A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Epoetin Alpha, Ferrous Sulfate
Study Phase: Phase 2
An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study
An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug
Study Drug: Lixivaptan
Study Phase: Phase 3
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Suspended
Publish Date: March 14, 2023
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
View 9 Less Clinical Trials

93 Total Publications

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.
Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.
Journal: European heart journal
Published: July 24, 2026
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Office

215 E Quincy St Ste 610, 
San Antonio, TX 
 (0.8 miles away)
210-226-2001
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Lisa Cabrera is a Nephrologist practicing medicine in San Antonio, Texas. Dr. Cabrera is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Diabetic Nephropathy, End-Stage Renal Disease (ESRD), Chronic Kidney Disease, and Nephrosclerosis. Dr. Cabrera is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

San Antonio Kidney Disease Center Physicians Group P.L.L.C.

7142 San Pedro Ave Ste 120, 
San Antonio, TX 
 (7.6 miles away)
210-661-5622
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Heather Banks is a Nephrologist practicing medicine in San Antonio, Texas. Dr. Banks is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Acute Kidney Failure, Chronic Kidney Disease, End-Stage Renal Disease (ESRD), and Low Sodium Level. Dr. Banks is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Sakdc Surgical Center PLLC

7114 San Pedro Ave, 
San Antonio, TX 
 (5.7 miles away)
210-342-2233
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajeev Narayan is a Nephrologist practicing medicine in San Antonio, Texas. Dr. Narayan is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Lactic Acidosis, Metabolic Acidosis, Respiratory Acidosis, Embolectomy, and Thrombectomy. Dr. Narayan is currently accepting new patients.

Frequently Asked Questions about Dr. Pablo E. Pergola

How do I make an appointment with Dr. Pablo E. Pergola?

You can book an appointment with Dr. Pablo E. Pergola by calling their office at 210-225-4733. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Pablo E. Pergola a top-rated expert for Alport Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Pablo E. Pergola is classified as an Elite expert for Alport Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Pablo E. Pergola specialize in?

While Dr. Pablo E. Pergola is a Nephrology, they have specific expertise in Alport Syndrome, High Potassium Level, and Chronic Kidney Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Nephrology.

Does Dr. Pablo E. Pergola participate in research or clinical trials?

Yes. Dr. Pablo E. Pergola has published 93 articles and abstracts on conditions like Alport Syndrome. You can view a list of Dr. Pablo E. Pergola's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Pablo E. Pergola accept my insurance?

Dr. Pablo E. Pergola accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 210-225-4733 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pergola's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile